### **Review Article**

# Title: Review of Current Evidence of Hydroxychloroquine in Pharmacotherapy of COVID-19

Umesh Devappa Suranagi<sup>\$#1</sup>, Harmeet Singh Rehan<sup>\$#1</sup>, Nitesh Goyal<sup>\*#2</sup>

\*Department of Pharmacology, Lady Hardinge Medical College & Associated Hospitals

New Delhi, India

\*Corresponding Author Name: Nitesh Goyal

Contact information: Department of Pharmacology, Lady Hardinge Medical College, New Delhi, India 110001

Email ID: <a href="mailto:drniteshgoyal@gmail.com">drniteshgoyal@gmail.com</a>

Ph-+91-9013964308

<sup>&</sup>lt;sup>1</sup> Highest Degree = MD

<sup>&</sup>lt;sup>2</sup> Highest Degree = MBBS

<sup>\$</sup> Equal contribution

**KEY POINTS** 

Question: What is the current evidence for use of Hydroxychloroguine in pharmacotherapy of

COVID-19?

Findings: We electronically explored various databases and clinical trial registries and identified

11 publications and 27 clinical trials with active recruitment. The in-vitro study data

demonstrates the viral inhibition by hydroxychloroquine. The clinical studies are weakly

designed and conducted with insufficient reporting and significant limitations. Well designed

robust clinical trials are being conducted all over the world and results of few such robust

studies are expected shortly.

Meaning: Current evidence stands inadequate to support the use of hydroxychloroquine in

pharmacotherapy of COVID-19.

**ABSTRACT** 

Importance: The COVID-19 Pandemic has literally left the world breathless in the chase for

pharmacotherapy. With vaccine and novel drug development in early clinical trials, repurposing

of existing drugs takes the center stage.

**Objective**: A potential drug discussed in global scientific community is hydroxychloroquine. We

intend to systematically explore, analyze, rate the existing evidence of hydroxychloroquine in

the light of published, unpublished and clinical trial data.

Evidence review: PubMed Ovid MEDLINE, EMBASE, Google scholar databases, pre-proof article

repositories, clinical trial registries were comprehensively searched with focused question of

use of hydroxychloroquine in COVID-19 patients. The literature was systematically explored as

per PRISMA guidelines.

**Findings**: Total 156 articles were available as of 7<sup>th</sup> May 2020; of which 11 articles of relevance

were analyzed. Three in-vitro studies were reviewed. Two open label non-randomized trials,

two open label randomized control trials, one large observational study, one follow-up study

and two retrospective cohort studies were systematically analyzed and rated by oxford CEBM

and GRADE framework for quality and strength of evidence. Also 27 clinical trials registered in

three clinical trial registries were analyzed and summarized. Hydroxychloroquine seems to be

efficient in inhibiting SARS-CoV-2 in in-vitro cell lines. However, there is lack of strong evidence

from human studies. It was found that overall quality of available evidence ranges from 'very

low' to 'low'.

Conclusions and relevance: The *in-vitro* cell culture based data of viral inhibition does not suffice for the use of hydroxychloroquine in the patients with COVID-19. Current literature shows inadequate, low level evidence in human studies. Scarcity of safety and efficacy data warrants medical communities, health care agencies and governments across the world against the widespread use of hydroxychloroquine in COVID-19 prophylaxis and treatment, until robust evidence becomes available.

# Introduction

The ongoing Coronavirus disease 2019 (COVID-19) pandemic has affected most of the countries in the world with unimagined infectious disease morbidity and mortality. As per WHO (as of 7th May, 2020), there has been a total of 3,672,238 confirmed cases and 254,045 deaths due to COVID-19 worldwide. However, no specific drug has been approved for the treatment of COVID-19 except the latest FDA emergency approval of remdesivir for use in severe cases. Recent updates indicate the vaccine quest is at least a year away. Building on experience from past Ebola and MERS pandemics, various human trials on novel pharmacotherapeutics are in progress.<sup>2</sup> Drugs such as remdesivir and favipiravir are in exploratory phases of clinical trials.<sup>3</sup> More than 20 other drugs such as chloroquine, hydroxychloroquine, lopinavir, ritonavir, human immunoglobulin, arbidol, oseltamivir, methylprednisolone, bevacizumab, interferons and traditional Chinese medicines are aimed at repositioning for COVID-19 treatment.<sup>4</sup> Forerunners among these are antimalarial drugs chloroquine and hydroxychloroquine, used extensively in treatment of malaria and elsewhere since many decades. 5,6 These drugs are 4-aminoquinoline derivatives exhibiting wide range of in-vitro activity against viruses. Their antiviral efficacy has been attributed to many different mechanisms. 7 Chloroquine is known to possess considerable broad-spectrum antiviral effects by interfering with the fusion process of viruses by increasing the local pH.8Other mechanisms include raise in endosomal pH in host cells thereby inhibiting auto-lysosome fusion and disrupting the enzymes needed for the viral replication. 9,10 Hydroxychloroguine (HCQ) is synthesized by N-hydroxyethyl side chain substitution of chloroquine. Although the antimalarial activity of HCQ is equivalent to that of chloroquine, HCQ is preferred over chloroquine owing to its lower ocular toxicity. <sup>11</sup>It is also used in the treatment of rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. In addition to endosomal pH increase, HCQ is also said to inhibit terminal glycosylation of ACE2 receptor, considered as target of SARS-CoV and SARS-CoV-2 cell entry. 12 The non-glycosylated ACE2 receptor might interact inefficiently with the SARS-CoV-2 spike protein, thus inhibiting the viral entry. 13 These myriad mechanisms of HCQ and its relative lesser toxicity profile as compared to chloroquine make it an attractive candidate in the pursuit of drug repositioning. In this highly demanding scenario of unmet need and steeply increasing morbidity and mortality of COVID-19, many government bodies and expert panels have recommended the use of chloroquine and HCQ for prophylaxis and treatment of COVID-19. 14-18 In such situation of urgency, there is a need to explore the current literature and critically analyze the existing evidence. We intend to conduct a detailed systematic search analysis of current literature and propose our findings.

## Materials and methods

#### **Data sources**

A comprehensive literature search was done independently by each author to find the role of HCQ in COVID-19 disease. PubMed Ovid MEDLINE, EMBASE, Google scholar databases were searched for existing literature from 2019 to 7<sup>th</sup> May 2020, 2020. The clinical trial Registries of the United States (clinicaltrials.gov), Chinese Clinical Trial Registry, WHO International clinical trial registry platform (ICTRP) were searched for ongoing registered studies. For preprint/preproof articles, repositories like BioRxiv, MedRxiv and ChemRxiv were searched.

Literature search

Search words included MeSH Terms (hydroxychloroguine OR HCQ) AND (COVID-19 OR Coronavirus OR nCov2 OR SARS-CoV2). We searched for both published and unpublished studies extensively. No language, time, study type and demographic filters were used. The search expansion was done using a snowballing method applied to the authors and references of selected publications. PRISMA guidelines were followed. Article search included abstracts, original experimental observational research, in-vitro studies, studies and controlled/uncontrolled trials. We excluded the articles like news items, magazine pieces, duplicate papers, review articles, editorials and letters to editor, expert opinions, perspectives, consensus statements and articles without the mention of the role of HCQ in COVID-19 or HCQ use in other conditions.

We searched databases of clinical trial registries using the search terms 'Hydroxychloroquine', 'HCQ', 'Plaquenil', 'COVID-19', 'SARS-CoV2', 'novel Corona virus' 'nCoV 2'. After identification and elimination of duplicated appearances, 96 clinical trials were found to be registered. Each database was further scanned and analyzed to remove the non-recruiting, inactive and cancelled trials, finally yielding 27 randomized control trials (RCTs) currently undergoing active recruitment for COVID-19 treatment with HCQ.


Screening, data extraction, data analysis, critical appraisal and evidence rating

Screening of articles was done independently by investigators according to titles, abstracts, summaries and conclusions. Methodical data extraction was done from selected articles and pertinent portions were identified, tabulated and presented systematically in the form of tables &summary. Randomized clinical trials with active recruitment were analyzed after collecting publically available information on various clinical trial databases. We used GRADE (Grading of Recommendations, Assessment, Development and Evaluations) framework methodology to rate the certainty of evidence from both published and unpublished clinical studies and Oxford center for evidence based medicine (CEBM) to assess and rate the quality of evidence.

Results

Total 156 articles were identified on initial search of databases. Following screening of titles and abstracts and removal of duplicates, eleven articles (three *in-vitro* studies, two open label non-randomized trials, two open label randomized control trials, one large observational study, one follow-up study, two retrospective cohort studies) were selected for further data extraction and analyses. Out of these 11, four clinical studies (one open label randomized control trial, one open label non-randomized trial and two retrospective cohort studies) were from pre-print servers. We also identified 96 clinical trials registered in three clinical trial registry databases. Methodical screening and analysis further yielded 27 RCTs currently undergoing active recruitment.

Figure1: PRISMA flow diagram



# In vitro studies of Hydroxychloroquine demonstrating anti-coronaviral activity

Yao et al, assessed the pharmacological activity of chloroquine and HCQ using SARS-CoV-2 infected Vero cells. Further as continued part of the study, they simulated physiologically-based pharmacokinetic models (PBPK) on the *in vitro* data obtained. The researchers found HCQ to be more potent than chloroquine to inhibit SARS -CoV-2 *in vitro*. Based on PBPK extrapolation, they recommended a loading dose of 400 mg twice daily of HCQ sulfate given orally, followed by a maintenance dose of 200 mg given twice daily for 4 days.<sup>19</sup>

In another correspondence report letter of an *in vitro* study by Liu et al, the investigators used VeroE6 cells and compared the antiviral activity of chloroquine versus HCQ against SARS-CoV-2 to determine different multiplicities of infection (MOIs) by quantification of viral RNA copy numbers. They found out that 50% maximal effective concentration (EC50) for HCQ was significantly higher than chloroquine and HCQ can efficiently inhibit SARS-CoV-2 infection *in vitro*.<sup>20</sup>

Previously in 2006, French researchers demonstrated that chloroquine and HCQ effectively inhibit both human and feline SARS COV in the infected Vero cells. EC50 for HCQ was significantly higher than chloroquine.<sup>21</sup> (Table 1)

Table 1: Summary of *in-vitro* studies showing efficacy of hydroxychloroquine against SARS-CoV-2 infected Cell lines

Authors,	Targeted	<b>D</b>	Models used for the	A att tool off and
country, year	virus	Drugs used	study	Antiviral effect

Yao X et al <sup>19</sup>	SARS-CoV-2	HCQ sulfate	Vero cells from African	50% maximal
China, 2020			green monkey in	effective
			Dulbecco's modified	concentration
		Chloroquine	eagle medium.	(EC50) HCQ
		phosphate	Further supplemented	(EC50=0.72 μM) was
			by Physiologically based	found to be more
			pharmacokinetic models	potent than CQ
			(PBPK) simulation	(EC50=5.47μM) <i>in</i>
				vitro.
Liu et al <sup>20</sup>	SARS-CoV-2	HCQ	African	EC 50 of Chloroquine
China, 2020			green monkey kidney	(2.71, 3.81, 7.14, and
			VeroE6 cells (ATCC-	7.36 μM) was
		Chloroquine	1586) was	significantly lower
			measured by standard	than HCQ (4.51, 4.06,
			CCK8 assay	17.31, and 12.96 μM)
Biotet al, <sup>21</sup>	Human	HCQ	Vero cells	Chloroquine: EC 50 =
France, 2006	SARS-CoV			6.5 ± 3.2 μM
				HCQ : EC 50 = 34 ± 5
		Chloroquine		μΜ
	Feline		Crandell–Reese feline	Chloroquine: EC 50 >
	coronavirus		kidney (CRFK)	0.8 μΜ
			cells	HCQ : EC 50 = 28 ± 27
				μМ

**Clinical studies conducted in COVID-19 patients** 

In the positive background of successful *in vitro* data and in the situation of an emerging epidemic, the Chinese authorities issued a consensus statement for the use of chloroquine in COVID-19 patients. <sup>14</sup>The earliest data of chloroquine administration in humans came from various parts of China in the form of collective reports were published by Gao et al. <sup>22</sup> The authors reported clinical experience data of treating more than 100 patients with chloroquine in various locations. They mentioned that chloroquine reduced the duration of illness and improved the pneumonia and pulmonary image changes in COVID-19 positive patients. The authors also recommended the drug to be included in the COVID-19 Guidelines issued by the National Health Commission of China for the use of drug in larger populations. <sup>23</sup>

The first empirical evidence of use of HCQ in humans was obtained by a small RCT conducted by Chen et al<sup>24</sup> in 30 adult COVID-19 patients. The treatment group received 400mg HCQ for 5 days, while the standard care was given to control group. The primary outcome was nasopharyngeal swab test results on Day 7. Investigators found that there is no difference between treatment and control group in the number of patients testing negative for COVID-19 on Day 7 (13 v/s 14), the duration of illness did not differ significantly (p= >0.05). There was one drop out and seven (three in treatment group and four in control) adverse events. The authors concluded that COVID-19 has good prognosis and larger sample size with better endpoints is needed to investigate the effects further.<sup>24</sup>

An open-label, non-randomized clinical trial was conducted by Gautret et al<sup>25</sup> in France with 36 patients diagnosed with COVID-19. HCQ in dose of 200mg three times daily was given to 20 patients for 10 days, additionally six patients in this group received azithromycin (500 mg on

day 1, 250mg on days 2-5) to prevent bacterial superinfection. The control group received standard care. The primary outcome was detection of SARS-CoV-2 RNA in nasopharyngeal samples. The authors reported that patients in the treatment group significantly differed for SARS-CoV-2 detection than controls. On Day 6 of post initiation, 70% of HCQ treated patients were virologically cured compared to 12.5% in the control group (p= 0.001). They concluded that HCQ treatment is significantly associated with viral load reduction/disappearance in COVID-19 patients and its effect is reinforced by azithromycin.<sup>25</sup>

A six-day pilot, uncontrolled, non-comparative observational follow-up study was conducted by French investigators to assess the clinical and microbiological effect of a combination of HCQ and azithromycin in 80 COVID-19 patients. The investigators reported that all patients but two (a 86 years old succumbed to illness, a 74 years old needed ICU) showed clinical improvement with the combination therapy. qPCR testing showed a rapid fall of nasopharyngeal viral load-83% and 93% patients were negative at Day 7, and Day 8 respectively. 97.5% of respiratory samples were negative for virus cultures at Day 5. The researchers urged to evaluate the combination strategy to treat patients in early course and avoid the spread of the disease. <sup>26</sup>

A latest large observational study conducted by American researchers, assessed the association between HCQ use and intubation or death. 1376 patients were followed up for median of 22.5 days. Among them, 811 (58.9%) patients received HCQ (600 mg twice on day 1, then 400 mg daily for a median of 5 days). Overall 346 patients (25.1%) had a primary end-point event (180 patients were intubated, of whom 66 subsequently succumbed, and 166 died without intubation). The authors reported that there was no significant association between HCQ use

and intubation or death. They concluded hydroxychloroquine administration was not associated with either a greatly lowered or an increased risk of the composite end point of intubation or death.<sup>27</sup> (Table 2)

Table 2: Summary of clinical studies with hydroxychloroquine treatment in COVID-19 patients

Authors	Study	Intervention/	Inclusion	Outcomes	Conclusion	Limitations/
country,	design	treatment	criteria			lacunae
year	Sample size					
	(treatment/					
	control)					
Chen J et	Open label	400mg of HCQ	-Age ≥18	At day 7 post-	Prognosis of	-Open label
al., <sup>24</sup>	randomized	P.O daily for 5	-Tested	inclusion, 86.7	COVID-19	design,
China	control trial	days	positive	% of HCQ	patients is	-weak
2020			for COVID-19	treated	good. Much	primary
	N=30 (15/15)			patients were	larger sample	endpoint,
	11 30 (13/13)			virologically	size is	-small
				cured as	needed for	sample size,
				compared to	better	-selection
				93.3% in the	assessment	and
				control group		confounding
				(p= >0.05)		bias
Gautret	Open label	200 mg of	-SARS-CoV-2	At day 6 post-	HCQ is	- Weak study

non	HCQP.O three	Carriage in	inclusion, 70%	significantly	design,
randomized	times a day for	nasopharyngea	of HCQ	associated	-Small
clinical trial	10 days; six	I	treated	with viral	sample size,
N=36 (20/16)	patients	sample	patients were	load	-six patients
	additionally	-Age >12 years	virologically	reduction/dis	drop out,
	received		cured as	appearance	-no long term
	azithromycinP.		compared	in COVID-19	follow up,
	0		12.5% in the	patients and	-No intention
	(500 mg on		control group	effect	to treat
	day 1, 250 mg		(p= 0.001)	reinforced	analysis,
	on days 2–5)			azithromycin	-No clinical
					endpoint.
Pilot	200mg of HCQ	-PCR RNA	Nasopharynge	Beneficial	-Non
uncontrolled	P.O TDS for 10	Tested positive	al viral load	evidence of	comparative
non	days +	COVID-19	83% negative	HCQ with	observational
comparative	Azithromycin	patients	at Day7, and	azithromycin	study
Observation	P.O 500mg day		93% at Day 8,	in COVID-19	- only mild
al follow-up	1 followed by	-mild illness	Viral culture	patients,	illness
study	250mg/day		negativity	early	included
	next 4 days		97.5% at Day5	reduction in	-No mention
N=80				contagiousne	of safety
11-00				SS	profile
Non	811 (58.9%)	Adult patients	346 patients	HCQ	-Non
comparative	patients	tested positive	(25.1%) had a	administratio	comparative
	randomized clinical trial N=36 (20/16)  Pilot uncontrolled non comparative Observation al follow-up study  N=80  Non	randomized times a day for clinical trial 10 days; six patients additionally received azithromycinP.  O (500 mg on days 2–5)  Pilot 200mg of HCQ uncontrolled P.O TDS for 10 non days + comparative Azithromycin Observation P.O 500mg day al follow-up 1 followed by study 250mg/day next 4 days  N=80  Non 811 (58.9%)	randomized times a day for clinical trial 10 days; six l sample additionally -Age >12 years received azithromycinP.  O (500 mg on days 2–5)  Pilot 200mg of HCQ -PCR RNA uncontrolled P.O TDS for 10 Tested positive non days + COVID-19 comparative Azithromycin patients Observation P.O 500mg day al follow-up 1 followed by study next 4 days  N=80  Non 811 (58.9%) Adult patients	randomized times a day for clinical trial 10 days; six I treated  N=36 (20/16) patients sample patients were additionally received azithromycinP.  O (500 mg on days 2–5)  Pilot 200mg of HCQ -PCR RNA Nasopharynge al viral load non days + COVID-19 83% negative comparative Azithromycin patients at Day7, and Observation P.O 500mg day next 4 days N=80  Non 811 (58.9%) Adult patients 346 patients	randomized times a day for clinical trial 10 days; six I treated with viral patients were additionally received azithromycinP.  Pilot 200mg of HCQ -PCR RNA Nasopharynge and days + COVID-19 at the comparative Azithromycin patients at Day7, and azithromycin patients at Day7, and azithromycin patients at Day7, and alfollow-up 1 followed by next 4 days Nasopharynge at 10 days patients, and some patients and at 10 days at 250 mg/day next 4 days Nasopharynge at 10 days at 10 days at 250 mg/day next 4 days Nasopharynge at 10 days at 10 days at 250 mg/day next 4 days Nasopharynge at 10 days at 250 mg/day next 4 days Nasopharynge at 10 days at 250 mg/day next 4 days Nasopharynge at 10 days at 250 mg/day next 4 days Nasopharynge at 250 mg/day next 4 days next 4 day

al, <sup>27</sup>	Observation	received	for COVID-19	primary end-	n was not	observational
USA.	al follow-up	hydroxychloro	with moderate	point event	associated	study
	study	quine (600 mg	to severe	(180	with either a	- single
	n= 1376	BD day 1, then	illness	intubations,	greatly	center design
		400 mg OD for		66	lowered or	-unmeasured
		5 days);		subsequent	an increased	confounding
		followed up		deaths, 166	risk of the	bias
		for median of		deaths	composite	- missing
		22.5 days		without	end point of	data
				intubation)	intubation or	possibility
					death	

# **Unpublished studies from preprint repositories**

We searched preprint servers for pre-proof, unpublished, approval awaited studies and articles. Since these studies are yet to be peer-reviewed we have briefly summarized their findings along with the limitations and lacunae. (Table 3)

Table 3: Summary of unpublished studies reporting the use of hydroxychloroquine in treatment of COVID-19 patients

Authors	Study	Intervention/	Inclusion	Outcomes	Conclusion	Limitations/
country,	design	treatment	criteria			lacunae
year,	Sample size					

Reposit	(treatment/					
ory/Jour	control)					
nal						
Chen Zet	Randomized	Standard care	-PCR RNA	Time taken for	Use of HCQ	-Small
al.,	control trial	+ HCQ P.O	Tested	clinical	could	sample size -
China	N=62	400mg/day for	positive	recovery, the	significantly	selection bias
2020	11-02	5 days	for COVID-	body	shorten TTCR	(only mild
			19,	temperature	and promote	illness
MedRxiv			with	recovery time	the absorption	included)
			SaO2/SPO2	and the cough	of pneumonia.	-confounding
			ratio > 93%	remission time		bias
			or	were		-Safety
			PaO2/FIO2	significantly		profile not
			ratio > 300	shortened in		detailed
				the HCQ		
			-mild illness	treatment		
				group		
Molina	Prospective	600mg/day of	PCR RNA	Nasopharynge	No evidence of	-Weak
et al.,	uncontrolled	HCQ for 10	Tested	al swabs in	a strong	design,
France;	single arm	days +	positive	8/10 patients	antiviral	-Small
2020	study	Azithromycin	COVID-19	were still	activity or	sample size
M´edeci	N= 11	500mg day 1	patients with	positive for	clinical benefit	-weak
ne et		followed by	severe illness	SARS-CoV2	of the	endpoints

Maladie		250mg/day	and co-	RNA at days 5	combination of	-selection
S		next 4 days	morbidities	to 6 after	HCQ and	bias
Infectie				treatment	azithromycin in	-brief report,
uses.				initiation	severe ill	-no mention
					COVID-19	of safety
					patients	profile.
Chorin et	Retrospectiv	Hydroxychloro	Patients with	30% of	QTc prolonged	Retrospectiv
al.,	e	quine +	positive	patients QTc	maximally	e study
USA	observationa	Azithromycin	SARS-CoV-2	increased by	from baseline	-Small
2020	l cohort	(to observe the	disease	> 40ms. In	between days	sample size
	safety study	change in QT		11% of	3 and 4	Brief report
MedRxiv	N= 84	interval)		patients QTc	representing	-Inclusion/
				increased to	high risk group	exclusion
				>500 ms,	for	criteria not
					arrhythmias	mentioned
Magagno	Retrospectiv	Hydroxychloro	Confirmed		No evidence	Retrospectiv
li et al.,	е	quine alone	SARS-CoV-2		that use of	e study
USA	observationa	(HCQ) vs.	infection		HCQ alone or	-selection
2020	l cohort	Hydroxychloro			HCQ/AZ	bias (all
	study	quine +			reduced the	patients
MedRxiv	N= 368	Azithromycin			risk of	above 65 yrs)
		along with			mechanical	-confounding
		standard care			ventilation in	bias

patients	CQ+ AZ)	
hospitalized		
with Covid-19.		
HCQ alone had		
increased		
association of		
overall		
mortality.		
HCQ alone had increased association of overall		

# Assessment of methodological quality and rating of evidence generated by clinical studies

We used GRADE framework approach (Figure 2) to assess the methodological quality of published and unpublished clinical studies of HCQ in COVID-19. The Oxford center for evidence based medicine (CEBM) levels of evidence was used to assess and rate the quality of evidence. Individual outcomes, overall outcome and clinical relevance were applied to rate the strength and quality of evidence. (Table 4)

Figure 2: Approach to rating of quality of evidence using GRADE methodology

STEP 1 – Initial level of Confidence rating		
Study design Initial confidence		
RCT	High Confidence	
Other type (non RCT, observational)	Low Confidence	

STEP 2 – Lowering or Raising Confidence		
Reasons for considering the change		
Lower if Higher if		

Risk of bias	Large effect
Inconsistency	Dose Response
Indirectness	
Imprecision	
Publication bias	

STEP 3- Final Level of Confidence Rating
Confidence in estimate of effect across
considerations
HIGH
++++
LOW
+++
LOW
++
VERY LOW
+

Table 4: Summary of assessment of quality and strength of evidence of clinical studies

Study	Study	Risk of	Inconsistency	Indirectness	Imprecision	Level of Evidence
	design	Bias				quality/strength
						rating
Chen J	RCT	Serious	Not serious	Not serious	Very serious	CEBM level: 2b
et al. <sup>24</sup>						GRADE level: Very Low (+)
Gautret	Non RCT	Very	Serious	Serious	Serious	CEBM level: 2b
et al. <sup>25</sup>		serious				GRADE level: Very Low (+)
Gautret	Observatio	Very	Serious	Serious	Serious	CEBM level: 2b
et al. <sup>26</sup>	nal study	serious				GRADE level: Very Low (+)
Geleris	Observatio	Serious	Serious	Serious	Very serious	EBM level: 2b
et al. <sup>27</sup>	nal study					GRADE level: Very Low (+)
Chen Z	RCT	Serious	Not serious	Serious	Not serious	CEBM level: 2b
et al.						GRADE level: Low (++)
(pre-						
print)						
Molina	Non RCT	Very	Not serious	Serious	Serious	CEBM level: 3b
et al.		serious				GRADE level: Very Low (+)
(pre-						

print)						
Chorin	Observatio	Very	Very serious	Not serious	Serious	CEBM level: 3b
et al.	nal study	serious				GRADE level: Very Low (+)
(pre-						
print)						
Magagn	Observatio	Very	Not serious	Not serious	Serious	CEBM level: 3b
oli et al.,	nal study	serious				GRADE level: Very Low (+)
(pre-						very Low (+)
print)						

# Summary of Ongoing Clinical trial data from clinical trial registry databases

Many of the ongoing RCTs conducted are studying the effect of HCQ compared to placebo(NCT04342221, NCT04333654, NCT04332991, NCT04331834), few of the RCTs have parallel design arms of HCQ and azithromycin (NCT04341727,NCT04341207, NCT04334382). Some RCTs have robust trial designs with quadruple masking and strong endpoints (NCT04333654, NCT04332991,NCT04331834). Few RCTs are in advance phases of clinical trials (NCT04316377, NCT04341493) and some studies have large sample size to measure the effect with higher strength of confidence (NCT04328012, NCT04328467). There are studies which are considering the safety endpoints in the main outcome measures (ChiCTR2000029868). Some RCTs are also testing antiretroviral drugs like lopinavir/ritonavir, emtricitabine/tenofovir along

with HCQ arm (NCT04328012,NCT04334928). Other studies are interested in tocilizumab (NCT04332094) and umefenovir/arbidol (ChiCTR2000029803) along with HCQ. Few of the studies are being conducted in severely ill patients (NCT04325893, ChiCTR2000029898) and some in mild infections of COVID-19 (NCT04307693, ChiCTR2000029899). Most of the studies are registered to be conducted in United States and China, others being conducted in Spain (NCT04331834, NCT04332094), Norway (NCT04316377), France (NCT04325893, NCT04341207), Germany (NCT04342221), Denmark (NCT04322396), Brazil (NCT04322123, NCT04321278), Mexico (NCT04341493) and Republic of Korea (NCT04307693). Few earlier studies registered in China (in Feb 2020) are nearing their completion in April end or early May 2020, their results can be expected in near future (ChiCTR2000029898, ChiCTR2000029899, ChiCTR2000029992). Additional details regarding the ongoing trials can be obtained from Supplementary Table 1.

In Europe, the Discovery project (NCT04315948) study has commenced in late march 2020 and with recruitment of 3100 patients. The four treatments set to be evaluated in the discovery

with recruitment of 3100 patients. The four treatments set to be evaluated in the discovery project as per WHO recommendations are Remdesivir, Lopinavir/Ritonavir, IFN $\beta$ -1a, Hydroxychloroquine/Chloroquine. The first set of results is expected to be available in 3 to 4 weeks of time. The estimated study completion date has been set in March 2023.<sup>28</sup>

# Discussion

As on 7<sup>th</sup> May 2020, COVID-19 pandemic has caused more than three and half million infections and more than 250,000 deaths growing up in alarming rate. Specific pharmacotherapy is the highest need of the world. Hydroxycholoroquine with relatively better safety profile than

choloroquine and possible better antiviral efficacy<sup>19</sup> offers a compelling hope. We systematically searched various databases and clinical trial registries to evaluate the evidence. During the previous outbreak of SARS, an in vitro study demonstrated the anti-corona viral effect of HCQ and choloroquine.<sup>21</sup> More recently Chinese researchers conducted in-vitro studies in cell lines and demonstrated the potential antiviral activity of HCQ against SARS-CoV2 as compared to chloroquine. 19,20 It is relevant to note that these studies were the basis of initial opinions and general consensus statements given by various panels across the world during the early stages of the pandemic. We found out that there is scarcity of well conducted and adequately reported human studies of HCQ use in COVID-19. This is in agreement with the other authors with similar findings of lack of literature in this regard. <sup>29-32</sup> Literature also lacks studies conducted in healthcare workers for either prophylaxis or treatment. Gao et al reported more than 100 patients with COVID-19 pneumonia showed clinical improvement and changes in image findings on chloroquine administration.<sup>22</sup> It is pertinent to note that this letter was the brief report of ongoing many trials in various locations in China, neither it mentioned any specific data regarding interventions, study design, study population and outcome measures, nor any adverse events were discussed. Chen et al in a RCT involving 30 COVID-19 patients did not find any significant difference between treatment and control group in both nasopharyngeal swab negativity and duration of illness.<sup>24</sup> This study was an open label trial with small sample size and had high risk of confounding and selection bias, the authors agreed that primary end point was weak and more robust end points with larger sample size is required to establish the effects.

Gautret et al<sup>25</sup> in a non-randomized clinical trial in 36 COVID-19 patients, reported viral load reduction by HCQ and its reinforcement by azithromycin. This study had major limitations in the form of small sample size, absence of randomization and masking, lack of intention to treat analysis and long term follow up, there was no clinical endpoint as outcome measure. A follow up study by Gautret et al in 80 COVID-19 patients reported 97.5% of respiratory samples were negative for virus cultures at Day 5. This study too involved only mild illness patients and did not report adverse effect profile and being an uncontrolled observational study, the strength of evidence tends to be low.<sup>26</sup> A latest large American observational study in 1376 patients reported no association between hydroxychloroquine administration and intubation/death in moderate to severe COVID-19 patients. This study had limitations of single center observational design, confounding bias and possibility of missing data events.<sup>27</sup>

We assessed the methodological quality and certainty of evidence of both published and unpublished clinical studies in existing literature and found that overall quality of available evidence ranges from 'very low' to 'low'; the Oxford CEBM rating used showed the quality of studies to be mostly at 3b level and couple studies at 2b level. (Table 4)

We also searched, identified and analyzed clinical trial databases to explore the ongoing active clinical trials (Supplementary Table 1) and found out relevant 27 clinical trials. Few trials among these are in advanced phases. Earlier registered Chinese clinical trials are expected to report the results in near future and robust designed RCTs elsewhere in the world are expected to produce their interim findings shortly henceforth.

It is appropriate to note that none of the available studies of HCQ in COVID-19 have emphasized on the adverse effects and toxicity profile of the drugs in treated patients. Even

though HCQ has relatively better safety profile than chloroquine, owing to its prolonged pharmacokinetics (537 hours half-life) and gradual elimination, HCQ has potential to cause various adverse events viz. gastrointestinal upset, <sup>33</sup> retinal toxicity, <sup>34</sup> fulminant hepatic failure, <sup>35</sup> severe cutaneous adverse reactions. <sup>36</sup> An important adverse effect of HCQ is cardiac conduction defects and ventricular arrhythmias. QT prolongation and arrhythmias can be precipitated by concomitant use of azithromycin. <sup>37</sup> Small but absolute risk of cardiovascular death is seen to be associated significantly with azithromycin as compared to fluoroquinolones. <sup>38</sup> Overdose or poisoning of HCQ is difficult to treat, caution is warranted in patients with hepatic and renal dysfunction, and regular ECG monitoring is advised in patients with cardiovascular diseases and in electrolyte imbalances. <sup>39</sup> Irrational use in general population without credible evidence may pose greater risk than benefit.

To best of our knowledge, this systematic review is the most comprehensive exploration and analysis of existing literature in this topic till date. Our systematic review has limitations in its rigor due to the inadequate, inconsistent data and heterogeneity of studies available. The rapidly expanding knowledge base of COVID-19 poses the possibility that some studies remain un-captured. However, we have tried our best to mitigate this by allowing broad, flexible search terms and by including many databases and preprint repositories, while remaining focused on the research question. In this background, we believe that expert opinions and clinical consensus statements given by various international authorities for the use of HCQ either as prophylaxis to high risk individuals <sup>15</sup> and healthcare professionals <sup>16</sup> or as emergency treatment of COVID-19 patients <sup>17,18</sup> lack strong evidence base.

Conclusion

The in-vitro cell culture based data of viral inhibition does not suffice for the use of hydroxychloroquine in the patients with COVID-19. Current literature shows scant and low level evidence in clinical studies. At this stage it is reasonable to suggest against the use hydroxychloroquine as prophylaxis both in general population as well as health care workers. Considering the toxicity profile, chances of overdoses and poisoning can pose serious health threats if hydroxychloroquine is used widely. Ongoing well designed clinical trials are expected to provide explicit answer on safety and efficacy in near future. It is warranted against the widespread use of hydroxychloroquine in COVID-19 until robust evidence becomes available.

# References

- WHO COVID-19 situation report 108. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200507covid-19-sitrep-108.pdf?sfvrsn=44cc8ed8\_2
- 2. Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug DiscovTher. 2020;14(1):58-60.
- 3. Lu CC, Chen MY, Chang YL. Potential therapeutic agents against COVID-19: What we know so far. J Chin Med Assoc. 2020 Apr 1. doi: 10.1097/JCMA.000000000000318. [Epub ahead of print]
- 4. Rosa SGV, Santos WC. Clinical trials on drug repositioning for COVID 19 treatment.

  RevPanamSaludPublica. 2020 Mar 20;44:e40.

- FDA Approved Drug Products: chloroquine phosphate Oral Tablets.
   https://www.accessdata.fda.gov/drugsatfda\_docs/label/2009/083082s050lbl.pdf.
- FDA Approved Drug Products: Hydroxychloroquine Oral Tablets.
   https://www.accessdata.fda.gov/drugsatfda docs/label/2019/0097680rig1s051lbl.pdf.
- 7. Ferner RE, Aronson JK. Chloroquine and hydroxychloroquine in covid-19. BMJ. 2020 Apr 8;369:m1432.
- 8. Gupta N, Agrawal S, Ish P. Chloroquine in COVID-19: the evidence. Monaldi Arch Chest Dis. 2020 Mar 31;90(1).
- 9. Salata C, Calistri A, Parolin C, Baritussio A, Palù G. Antiviral activity of cationic amphiphilic drugs. Expert Rev Anti Infect Ther2017;15:483-92.
- Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?. Int J Antimicrob Agents.
   Mar 11;:105938. doi: 10.1016/j.ijantimicag.2020.105938. [Epub ahead of print]
   PubMed PMID: 32171740.
- 11. Tan YW, Yam WK, Sun J, Chu JJH. An evaluation of chloroquine as a broad-acting antiviral against hand, foot and mouth disease. Antiviral Res 2018;149:143–9.
- 12. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) *in vitro*. Cell Res 2020;30:269–71.Yao X et al., 2020.

- 13. Zhou D, Dai SM, Tong Q. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J AntimicrobChemother. 2020 Mar 20;. doi: 10.1093/jac/dkaa114. [Epub ahead of print] PubMed PMID: 32196083.
- 14. ZhonghuaJie He Hu Xi ZaZhi. [Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia]. 2020 Mar 12;43(3):185-188. doi: 10.3760/cma.j.issn.1001-0939.2020.03.009.
- 15. FDA: Emergency Use Authorization of Medical Products and Related Authorities. https://www.fda.gov/media/97321/download
- 16. Indian Council for Medical Research. Recommendation for empiric use of hydroxychloroquine for prophylaxis of SARS-CoV-2 infection. https://icmr.nic.in/sites/default/files/upload\_documents/HCQ\_Recommendation\_22March final MM V2.pdf. Accessed 3 April 2020
- 17. FDA: Emergency Use Authorization Information. https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization
- 18. Lenzer J. Covid-19: US gives emergency approval to hydroxychloroquine despite lack of evidence. BMJ 2020;369:m1335. 10.1136/bmj.m1335 32238355.
- 19. Yao X, Ye F, Zhang M, et al. *In vitro* antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory

- syndromecoronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020. doi:10.1093/cid/ciaa237. [Epub ahead of print: 9 Mar 2020]
- 20. Liu, J., Cao, R., Xu, M. et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov 6, 16 (2020). https://doi.org/10.1038/s41421-020-0156-0.
- 21. Biot C, Daher W, Chavain N, et al. Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities. J Med Chem. 2006. 49(9): 2845-9.
- 22. Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 2020; 14(1): 72–. DOI: https://doi.org/10.5582/bst.2020.01047.
- 23. Chinese Clinical Guidance for COVID-19 Pneumonia Diagnosis and Treatment (7th edition)

  [Internet]. China National Health Commision; 2020. Available from:

  http://kjfy.meetingchina.org/msite/news/show/cn/3337.html#
- 24. Chen J, Liu D, Liu L, et al. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19). Journal of ZheJiang University (Medical Sciences) 2020; 49(1).
- 25. Gautret P, Lagier J-C, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020; 105949: 105949. DOI: https://doi.org/10.1016/j.ijantimicag.2020.105949.

- 26. Gautret P, Lagier JC, Parola P, et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. Travel Med Infect Dis. 2020;101663. doi:10.1016/j.tmaid.2020.101663[Epub ahead of print].
- 27. Geleris J, Sun Y, Platt J. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med 2020. DOI: 10.1056/NEJMoa2012410.
- 28. Vanden Eynde JJ1. COVID-19: A Brief Overview of the Discovery Clinical Trial.

  Pharmaceuticals (Basel). 2020 Apr 10;13(4). pii: E65. doi: 10.3390/ph13040065.
- 29. Pacheco RL, Riera R. Hydroxychloroquine and chloroquine for COVID-19 infection. Rapid systematic review. J ÉvidBasedHealthc. 2020;2(1):xx-xx. doi: 10.17267/2675-021Xevidence. v2i1.2843.
- 30. Singh AK, Singh A, Shaikh A, Singh R, Misra A. Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries. Diabetes MetabSyndr. 2020;14(3):241–246. doi:10.1016/j.dsx.2020.03.011
- 31. Ferner RE, Aronson JK. Choloroquine and Hydroxychloroquine in COVID-19. BMJ 2020;369:m1432. doi: 10.1136/bmj.m1432.
- 32. Sinha N, Balayla G. Hydroxychloroquine and covid-19. Postgrad Med J. 2020. doi:10.1136/postgradmedj-2020-137785 [Epub ahead of print, 2020 Apr 15].

- 33. Srinivasa A, Tosounidou S, Gordon C. Increased incidence of gastrointestinal side effects in patients taking hydroxychloroquine: a brand-related issue? J Rheumatol 2017; 44(3):398.
- 34. Mavrikakis M, Papazoglou S, Sfikakis PP, et al. Retinal toxicity in long term hydroxychloroquine treatment. Ann Rheum Dis 1996; 55(3): 187–189.
- 35. Makin AJ, Wendon J, Fitt S, Portmann BC, Williams R. Fulminant hepatic failure secondary to hydroxychloroquine. Gut 1994;35:569-70.
- 36. Murphy M, Carmichael AJ. Fatal toxic epidermal necrolysis associated with hydroxychloroquine. ClinExpDermatol2001;26:457-8.
- 37. Chen CY1, Wang FL, Lin CC. Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia. Clin Toxicol (Phila). 2006;44(2):173-5.
- 38. Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and risk of cardiovascular death. N Engl J Med 2012; 366:1881-18.
- 39. Bauman JL1, Tisdale JE2. Chloroquine and Hydroxychloroquine in the Era of SARS CoV2: Caution on Their Cardiac Toxicity. Pharmacotherapy. 2020 Apr 13. doi: 10.1002/phar.2387.

# Supplementary table 1 Ongoing Clinical trial data from clinical trial registry databases

SI. no	Title	Trial Reg number	Intervention	Comparator	Study Design	Main outcome(s)	Populatio n	Place/ Country	Expecte d Timeline
01	Hydroxychloroquin e for COVID-19 Study	NCT043422 21	Hydroxychloroqui ne Sulfate	Placebo	Phase 3 RCT, quadruple masking	Effect of HCQ on in vivo viral clearance	N= 220 18 Yrs to 99 Yrs (Adult, Older Adult) All sex	Germany	Start- Mar 29, 2020 End- Mar 2021
02	Hydroxychloroquin e,Azithromycin in the Treatment of SARS CoV-2 Infection (WU352)	NCT043417 27	Hydroxychloroqui ne Sulfate  Azithromycin  Chloroquine sulfate	-	Open label RCT, parallel design	Hours to recovery, Time fever resolution	N= 500 18 Yrs (Adult, Older Adult) All sex	USA	Start- Apr 4, 2020 End- Apr 1 2021

03	Hydroxychloroquin e vs Nitazoxanide in Patients With COVID-19 Study	NCT043414 93	Nitazoxanide 500 mg Hydroxychloroqui ne	-	Phase 4 RCT, single masking, parallel design	Mechanical ventilation requiremen t	N= 86 5 Yrs and older (child Adult, Older Adult) All sex	Mexico	Start- Apr 6, 2020 End- Aug 30, 2020
04	Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease in French Cancer Patients Study	NCT043412 07	Hydroxychloroqui ne Azithromycin	-	Phase 2 , non randomis ed Open label trial	Prevalence and the 3- months incidence of SARS-CoV-2 in cancer patients	N= 1000 18 Yrs and older(Adu It, Older Adult) Both sex	France	Start- Apr 3, 2020 End- Apr2022
05	Hydroxychloroquin e vs. Azithromycin for Outpatients in Utah With COVID- 19 Study	NCT043343 82	Hydroxychloroqui ne Azithromycin	-	Phase 3 Open label, parallel design RCT	Hospitalizati on within 14 days of enrolment, Duration of COVID-19- attributable symptoms	N= 1550 45 Yrs and older(Adu lt, Older Adult) All sex	USA	Start- Apr 2, 2020 End- Dec 31 2021

06	Hydroxychloroquin e in Outpatient Adults With COVID- 19 Study	NCT043336 54	Hydroxychloroqui ne SAR321068	Placebo	Phase 1 RCT, parallel	Change from baseline to Day 3 in	N= 210 18 Yrs and	USA	Start- Mar 31, 2020
					design, quadruple masking	nasopharyn geal SARS- CoV-2 viral load	older(Adu lt, Older Adult) All sex		May 2020
07	Outcomes Related to COVID-19 Treated With Hydroxychloroquin e Among In- patients With Symptomatic Disease Study	NCT043329 91	Hydroxychloroqui ne	Placebo	Phase 3 RCT, parallel design, quadruple masking	COVID Ordinal Outcomes Scale on Day 15, all-location, all-cause mortality assessed on day 15	N= 510 18 Yrs and older(Adu It, Older Adult) All sex	USA	Start- Apr, 2020 End- Apr 2021

08	Clinical Trial of Combined Use of Hydroxychloroquin e, Azithromycin, and Tocilizumab for the Treatment of COVID-19 Study	NCT043320 94	Tocilizumab  Hydroxychloroqui ne  Azithromycin	-	Phase 2Open label, parallel design RCT	In-hospital mortality Need for mechanical ventilation in ICU	N= 276  18 Yrs and older(Adu lt, Older Adult)  All sex	Spain	Start- Apr, 2020 End- Sep 2020
09	Pre-Exposure Prophylaxis With Hydroxychloroquin e for HighRisk Healthcare Workers During the COVID-19 Pandemic Study	NCT043318 34	Hydroxychloroqui ne	Placebo	Phase 3 RCT, parallel design, quadruple masking	Confirmed cases of a COVID-19, SARS-CoV-2 seroconvers ion	N= 440  18 Yrs and older(Adu lt, Older Adult)  All sex	Spain	Start- Apr 3, 2020 End-Oct 3, 2020
10	Hydroxychloroquin e vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID- 19 Study	NCT043298 32	Hydroxychloroqui ne Azithromycin	-	Phase 2 open label, parallel design RCT	COVID Ordinal Outcomes Scale at 14 days Hospital- free days at 28 days	N= 300 18 Yrs and older(Adu It, Older Adult All sex	USA	Start- Mar 30, 2020 End- Dec 31, 2020

11	Pre-exposure Prophylaxis for SARS-Coronavirus-2	NCT043284 67	Hydroxychloroqui ne	Placebo	Phase 3 RCT, parallel design, quadruple masking	COVID-19- free survival Incidence of confirmed SARS-CoV-2 detection	N= 3500 18 Yrs and older(Adu It, Older Adult All sex	USA	Start- Apr 2020 End- Aug 2020
12	COVID MED Trial - Comparison Of Therapeutics for Hospitalized Patients Infected With SARSCOV-2	NCT043280 12	Lopinavir/ ritonavir  Hydroxychloroqui neSulfate  Losartan	Placebo	Phase 2 Phase 3 RCT, parallel design, quadruple masking	National Institute of Allergy and Infectious Diseases COVID-19 Ordinal Severity Scale (NCOSS)	N= 4000 18 Yrs and older(Adu It, Older Adult All sex	USA	Start- Apr 6, 2020 End-Jan 1, 2021

13	Hydroxychloroquin	NCT043258	Hydroxychloroqui	Placebo	Phase 3	Number of	N= 1300	France	Start-
	e Versus Placebo in	93	ne		RCT,	death from			Apr
	COVID-19 Patients					any cause,	18 Yrs		2020
	at Risk for Severe				parallel	or the need	and		
	Disease				design,	for	older(Adu		End- Sep
					doublema	intubation	lt, Older		2020
					sking	and	Adult		
					38	mechanical	All sex		
						ventilation	, iii sex		
						during the			
						14 days			
						following			
						inclusion			
						and start of			
						treatment			
14	Proactive	NCT043223	Azithromycin	Placebo	Phase 2	Number of	N= 226	Denmark	Start-
	Prophylaxis With	96				days alive	Child,		Apr
	Azithromycin and				RCT,	and	Adult,		2020
	Chloroquine in		Hydroxychloroqui		parallel	discharged	Older		
	Hospitalized		ne		design,	from	Adult		End-Oct
	Patients With					hospital			2020
	COVID-19				quadruple	within 14	All sex		
					masking	days			

15	Safety and Efficacy	NCT043221	Hydroxychloroqui	-	Phase 3	Evaluation	N= 630	Brazil	Start-
	of Hydroxychloroquin e Associated With Azythromycin in SARSCov-2 Virus	23	ne Oral Product  Hydroxychloroqui ne + azithromycin		open label RCT, parallel design	of the clinical status Ordinal scale in 7 days	18 Yrs and older(Adu It, Older Adult All sex		Apr 6, 2020 End- Aug 2020
16	Safety and Efficacy of Hydroxychloroquin e Associated With Azithromycin in SARSCoV2 Virus (Coalition Covid-19 Brasil II)	NCT043212 78	Hydroxychloroqui ne + azithromycin Hydroxychloroqui ne	-	Phase 3 open label RCT, parallel design	Evaluation of the clinical status All-cause mortality	N= 440  18 Yrs and older(Adu lt, Older Adult All sex	Brazil	Start- Mar 28 , 2020 End- Aug 30, 2020
17	Norwegian Coronavirus Disease 2019	NCT043163 77	Hydroxychloroqui nesulfate		Phase 4 open label RCT, parallel design	Rate of decline in SARSCoV-2 viral load	N= 202  18 Yrs and older(Adu lt, Older Adult All sex	Norway	Start- Mar 25 , 2020 End- Apr 1, 2021

18	Post-exposure Prophylaxis / Preemptive Therapy for SARSCoronavirus-2	NCT043086 68	Hydroxychloroqui ne	Placebo	Phase 3  RCT,  parallel design,  quadruple masking	Incidence of COVID19 Disease among asymptoma tic at trial entry	N= 3000 18 Yrs and older(Adu It, Older Adult All sex	USA	Start- Mar 17 , 2020 End- Apr 21, 2021
19	Comparison of Lopinavir/ Ritonavir or Hydroxychloroquin e in Patients With Mild Coronavirus Disease (COVID-19)	NCT043076 93	Lopinavir/ ritonavir Hydroxychloroqui neSulfate	-	Phase 2 open label RCT, parallel design	Viral load Viral load change  Time to clinical improveme nt (TTCI)	N= 150 16 to 99 Yrs (Adult, Older Adult All sex	Republic of Korea	Start- Mar, 2020 End- May, 2021
20	Randomized Clinical Trial for the Prevention of SARSCoV-2 Infection (COVID- 19) in Healthcare Personnel	NCT043349 28	Emtricitabine/ tenofovirdisoprox il  Hydroxychloroqui ne	Placebo	Phase 3 RCT, parallel design, Doublema sking	Number of confirmed symptomati c infections of SARS- CoV-2 (COVID-19)	N= 4000 18 Yrs and older(Adu It, Older Adult All sex	Spain	Start- Apr 1 2020 End- June 30 2021

21	A prospective, open label, randomized, control trial for chloroquine or hydroxychloroquin e in patients with mild and common novel coronavirus pulmonary (COVID-19)	ChiCTR2000 030054	Hydroxychloroqui ne sulfate 0.2g bid x 14 days  The first dose of chloroquine phosphate 1gx2 days, and the third day 0.5gx12 days	Standard of care	Prospecti ve open label RCT	Clinical recovery time  Time to 2019-nCoV RT-PCR negativity in upper and lower respiratory tract specimens	N= 100 18 to 75 Yrs All sex	China	Start- Feb 22 2020 End- May 5 2020
22	A prospective, randomized, open label, controlled trial for chloroquine and hydroxychloroquin e in patients with severe novel coronavirus pneumonia (COVID-19)	ChiCTR2000 029992	Chloroquine phosphate1.0gx2 days for the first dose, 0.5gx12 day from the third day  Hydroxychloroqui ne sulfate 0.2g bid x 14 days	Standard of care	open labefl RCT	Clinical recovery time.  Changes in viral load of upper and lower respiratory tract samples compared with the baseline	N= 100 18 to 75 Yrs All sex	China	Start- Feb 17 2020 End- May 5 2020

23	Evaluation the	ChiCTR2000	Hydroxychloroqui	-	open	Time to	N= 100	China	Start-
	Efficacy and Safety	029899	nesulfate		label RCT,	Clinical			Feb 17
	of				parallel	recovery	18 Yrs		2020
	Hydroxychloroquin		Day1: first dose: 6		design		and		
	eSulfate in		tablets (0.1g/tablet),				above		
	Comparison with		second dose: 6			All-cause	All sex		End- Apr
	Phosphate		tablets		mortality of 28-days	,		30 2020	
	Chloroquine in Mild		(0.1g/tablet) aft			20-uays	<u> </u>		
	and Common		er 6h ; Day2-5: 2						
	Patients with Novel		tablets						
	Coronavirus		(0.1g/tablet),						
	Pneumonia		BID						
	(COVID-19): a Randomized, Open-	Chloroquine phosphate							
	label, Parallel,	el, Parallel,							
	Controlled Trial		Day1-3: 500mg,						
			BID Day4-5:						
			250mg, BID						

24	Evaluation the Efficacy and Safety of Hydroxychloroquin eSulfate in Comparison with Phosphate Chloroquine in Severe Patients with Novel Coronavirus Pneumonia (COVID-19): a	ChiCTR2000 029898	Hydroxychloroqui nesulfate  Day1: first dose: 6 tablets (0.1g/tablet) , second dose: 6 tablets (0.1g/tablet) aft er 6h ; Day2-5: 2 tablets   (0.1g/tablet), BID  Chloroquine	-	open label RCT, parallel design	Time to Clinical recovery All-cause mortality of 28-days	N= 100 18 Yrs to 75yrs All sex	China	Start- Feb 17 2020 End- Apr 30 2020
	Randomized, Open- Label, Parallel, Controlled Trial		Day1-3: 500mg, BID Day4-5: 250mg, BID						
25	Hydroxychloroquin e treating novel coronavirus pneumonia (COVID-19): a	ChiCTR2000 029868	Hydroxychloroqui ne sulfate	Standard of care	open label multicent er RCT,	Viral nucleic acids Adverse events	N= 360 18 yrs and above	China	Start- Feb 6 2020
	randomized controlled, open label, multicenter trial						All sex		End- June 30 2020

26	A prospective, randomized, open-label, controlled clinical study to evaluate the preventive effect of hydroxychloroquin e on close contacts after exposure to the Novel Coronavirus Pneumonia (COVID-19)	ChiCTR2000 029803	Hydroxychloroqui ne, small and high dose 2 arms  Abidol small and high dose 2 arms	-	Prospecti ve open label RCT	Number of patients who have progressed to suspected or confirmed within 24 days of exposure to new coronavirus	N= 320  18 yrs to 60 yrs  All sex  Four arms total with 80 patients each	China	Start- Feb 20 2020 End- Feb 20, 2021
27	Therapeutic effect of hydroxychloroquin e on novel coronavirus pneumonia (COVID-19)	ChiCTR2000 029559	Hydroxychloroqui ne 0.1g oral 2 times/ day  Hydroxychloroqui ne 0.2g oral 2 times/ day	Placebo	Prospecti ve placebo controlled RCT	The time when the nucleic acid of the novel coronavirus turns negative	N= 300 30 yrs to 65 yrs All sex Three arms total with 100 patients each	China	Start- Jan 31 2020 End- Feb 29, 2020